Sun Pharma Demands Generic Cancer Drug Market Exclusivity
By Kurt Orzeck ( March 1, 2013, 10:38 PM EST) -- Sun Pharmaceutical Industries Ltd. urged a District of Columbia federal judge Friday to block the U.S. Food and Drug Administration from approving any generic versions of the oncology drug Zometa until the agency decides whether to grant 180-day market exclusivity to the Indian drugmaker....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.